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Abstract
Background: IMbrave150 is a phase III trial that assessed atezolizumab + bevaci-
zumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepa-
tocellular carcinoma (HCC) and demonstrated a significant improvement in clinical 
outcomes. Exploratory analyses characterized objective response rate (ORR), depth 
(DpR), and duration of response (DoR), and patients with a complete response (CR).
Methods: Patients were randomized 2:1 to intravenous ATEZO (1200 mg) + BEV 
(15 mg/kg) every 3 weeks or oral SOR (400 mg) twice daily. Tumors were evaluated 
using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and 
HCC- modified RECIST (mRECIST). ORR by prior treatment and largest baseline 
liver lesion size, DoR, time to response (TTR), and complete response (TTCR) were 
analyzed.
Results: For both criteria, responses favored ATEZO/BEV versus SOR regardless 
of prior treatment and in patients with lesions ≥3 cm. Median TTR was 2.8 months 
per RECIST 1.1 (range: 1.2– 12.3  months) and 2.8  months per mRECIST (range: 
1.1– 12.3 months) with ATEZO/BEV. Patients receiving ATEZO/BEV had a greater 
DpR, per both criteria, across baseline liver lesion sizes. Characteristics of complete 
responders were similar to those of the intent- to- treat population. In complete re-
sponders receiving ATEZO/BEV per mRECIST versus RECIST 1.1, respectively, 
median TTCR was shorter (5.5 vs. 7.0 months), mean baseline sum of lesion diameter 
was longer (5.0 [SD, 5.1] vs. 2.6 [SD, 1.4] cm), and mean largest liver lesion size was 
larger (4.8 [SD, 4.2] vs. 2.3 [SD, 1.0] cm).
Conclusions: These data highlight the improved ORR, DpR, and CR rates with 
ATEZO/BEV in unresectable HCC.
K E Y W O R D S
hepatocellular carcinoma, immunotherapy, Response Evaluation Criteria in Solid Tumors
5438 |   SALEM Et AL.
1 |  INTRODUCTION
Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 
1.1) is the established method for assessing the objective re-
sponse rate (ORR).1,2 It was developed for evaluating cyto-
toxic drugs, and it posits that tumor shrinkage is reflective 
of antitumor activity.3 Further delving into ORR, depth of 
response (DpR), a concept thoroughly described in colorectal 
cancer, aims to quantify the magnitude of response. DpR is 
poorly studied in hepatocellular carcinoma (HCC).4- 7
The use of RECIST 1.1 is controversial for assessing re-
sponse to systemic therapy for HCC, given that these ther-
apies mechanistically decrease tumor vascularity but may 
leave tumor size unaffected. The net effect is an underreport-
ing of ORR.8 In addition, the assessment of progressive dis-
ease (PD) in HCC may be misinterpreted when relying solely 
on RECIST 1.1, due to imaging features associated with the 
natural history of cirrhosis (ascites, lymph node enlarge-
ment) that may be confused with PD.9 To account for the 
limitations of RECIST 1.1, HCC- specific modified RECIST 
(mRECIST) was developed using contrast enhancement to 
identify viable lesions, incorporating vascular invasion, and 
explicitly defining patterns of progression, to ensure that PD 
is not inaccurately overreported.8,9
IMbrave150 (NCT03434379) is a randomized phase III 
trial that assessed atezolizumab +  bevacizumab (ATEZO/
BEV) versus sorafenib (SOR) in patients with unresectable 
HCC who had not received prior systemic therapy.10 In the 
primary analysis (data cutoff: August 29, 2019), ATEZO/
BEV resulted in a significant improvement in overall sur-
vival (OS) and progression- free survival (PFS) compared 
with SOR, leading to regulatory approval and to becoming 
the new non- tyrosine kinase inhibitor standard of care in this 
patient population.10,11
Further, after 12 months of additional follow- up, ATEZO/
BEV maintained clinically meaningful survival benefits over 
SOR and a safety profile consistent with the primary analy-
sis. In light of recent data on the antitumoral effects of immu-
notherapies,12- 15 we conducted further investigation with a 
post hoc analysis of the updated ORR, DpR, and complete re-
sponse (CR) observed with immunotherapies in IMbrave150.
2 |  MATERIALS AND METHODS
2.1 | Study design
Patients were randomly assigned (2:1) to receive intrave-
nous ATEZO (1200 mg) (anti- programmed death- ligand 1; 
PD- L1) + BEV (15 mg/kg) (anti- VEGF) every 3 weeks or 
oral SOR (multikinase inhibitor) 400  mg twice daily until 
unacceptable toxicity or loss of clinical benefit.10 Eligibility 
criteria and randomization procedures have been described 
previously.10 Randomization stratification factors included 
geographic region (Asia excluding Japan vs. rest of world); 
macrovascular invasion (MVI), extrahepatic spread (EHS) of 
disease (presence vs. absence), or both; and baseline alpha- 
fetoprotein level (<400 vs. ≥400 ng/ml).
Coprimary endpoints were OS and PFS by blinded inde-
pendent central review (BICR)- assessed RECIST 1.1. Key 
secondary endpoints included ORR and duration of response 
(DoR) per RECIST 1.1 and mRECIST.8 ORR by both re-
sponse criteria was tested as part of a statistical hierarchy and 
was defined as the percentage of patients with a CR or partial 
response (PR). A confirmed objective response was defined 
as having been observed at two consecutive tumor assess-
ments ≥28  days apart. DoR was defined as the time from 
first documented CR or PR to disease progression or death. 
Time to response (TTR) was defined as the time from ran-
domization to the first confirmed response (either CR or PR) 
in all responders, and time to complete response (TTCR) was 
defined as the time from randomization to the first confirmed 
CR in all complete responders. DpR was defined as the per-
centage of tumor shrinkage based on longest diameter (LD), 
observed at the lowest point (nadir) compared with baseline. 
Tumors were assessed by computed tomography or magnetic 
resonance imaging at baseline and every 6 weeks until week 
54, then every 9 weeks thereafter. Responses were analyzed 
by BICR with two independent radiologists and imaging ad-
judication by a third if there was a discrepancy.
Enrolled patients provided written informed consent. The 
study's protocol (available in the online supplement on the 
journal's website) was approved by each site's institutional 
review committee, and the study was conducted according 
to the ethical guidelines of the 1975 Declaration of Helsinki.
2.2 | Current analyses
For ORR analyses, the ORs relative to SOR and the asso-
ciated Wald 95% confidence intervals were estimated using 
logistic regression. ORR in the intent- to- treat (ITT) popula-
tion with measurable disease at baseline was summarized 
by baseline characteristics and prior treatment, such as prior 
transarterial chemoembolization (TACE) (none, 1 or 2, or 3+ 
treatments) or baseline largest liver lesion (<3, ≥3 to <5, ≥5 
to <7, or ≥7 cm).
DpR was determined by both minimum reduction (i.e., 
minimum percent change) in the sum of longest diameter 
(SLD) and the LD in the largest liver lesion for RECIST 1.1 
and mRECIST in all patients and in subgroups according to 
baseline liver lesion size.
To better characterize patients who achieved a RECIST 
1.1 or mRECIST CR, parameters such as baseline sum of tar-
get lesion; largest liver lesion size; number of prior TACE or 
doxorubicin- eluting beads TACE (DEB- TACE); Barcelona 
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Clinic Liver Cancer (BCLC) stage at study entry; etiology; 
and presence of EHS, MVI, or both were descriptively an-
alyzed. The full statistical analysis plan is available in the 
online supplement on the journal's website.
3 |  RESULTS
At the time of the clinical cutoff date for the updated analysis 
(August 31, 2020), the ORR was 30% (95% CI: 25%– 35%) 
with ATEZO/BEV and 11% (95% CI: 7%– 17%) with SOR per 
BICR RECIST 1.1, and 35% (95% CI: 30%– 41%) and 14% 
(95% CI: 9%– 20%), respectively, per mRECIST.10 Among 
responders (PR or CR), the median TTR with ATEZO/
BEV was similar for both RECIST 1.1 and mRECIST 
(2.8 months; range: 1.2– 12.3 months and 2.8 months; range: 
1.1– 12.3  months, respectively). In patients receiving SOR, 
the median TTR per mRECIST was shorter (2.6  months; 
range: 1.2– 9.7  months) than per RECIST 1.1 (3.3  months; 
range: 1.2– 5.7 months).
3.1 | Objective response rate
To better understand the potential effect of tumor char-
acteristics and prior locoregional therapy (LRT) when 
comparing ATEZO/BEV with SOR, we assessed ORR by 
largest lesion size and number of prior TACE/DEB- TACEs 
(Figure 1). For this analysis, LRT refers to chemoemboliza-
tion or chemoembolization with drug- eluting beads (TACE 
or DEB- TACE).
3.1.1 | Analysis by largest target liver lesion 
at baseline
Response in patients with largest target liver lesions ≥3 
to <5, ≥5 to <7, or ≥7 cm favored ATEZO/BEV by both 
RECIST 1.1 (OR, 7.1 [95% CI: 1.5– 33.3]; OR, 3.3 [95% CI: 
0.4– 29.1]; and OR, 4.7 [95% CI: 1.3– 16.7], respectively) and 
mRECIST (OR, 5.2 [95% CI: 1.4– 19.2]; OR, 6.7 [95% CI: 
0.8– 56.5]; OR, 3.9 [95% CI: 1.3– 12.0], respectively). In pa-
tients who had lesions <3 cm, response also favored ATEZO/
BEV per mRECIST (OR, 1.8 [95% CI: 0.8– 4.0]).
3.1.2 | Analysis by prior LRT
Response rates were higher in the ATEZO/BEV arm than in 
the SOR arm, regardless of the number of prior LRTs for 
both BICR response criteria (Figure  1). The highest ORR 
was observed with ATEZO/BEV versus SOR in patients who 
F I G U R E  1  BICR- assessed ORR per (RECIST 1.1 and mRECIST) in IMbrave150. ATEZO, atezolizumab; BEV, bevacizumab; BICR, blinded 
independent central review; CR, complete response; DEB- TACE, doxorubicin- eluting beads transarterial embolization; HCC, hepatocellular 
carcinoma; mRECIST, HCC- modified Response Evaluation Criteria in Solid Tumors; ORR, objective response rate; PR, partial response; RECIST 
1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SOR, sorafenib; TACE, transarterial chemoembolization. aNumber of responders. 
Responders refer to all patients with CR or PR. A window of 28 days was used for the confirmation of CR or PR. OR relative to SOR and the 
associated Wald 95% CIs were estimated using unstratified logistic regression
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received one or two prior LRTs (37.1% vs. 7.1% per RECIST 
1.1; 45.2% vs. 9.5% per mRECIST).
3.2 | Depth of response
3.2.1 | SLD % change
In the ITT population, patients receiving ATEZO/BEV had 
a greater DpR than those receiving SOR, regardless of BICR 
response criteria (Table  1). The mean (SD) minimum per-
centage SLD change was larger in the ATEZO/BEV arm than 
in the SOR arm per RECIST 1.1 (−27.3 [SD, 38.8] and −6.1 
[SD, 29.4] in the ATEZO/BEV and SOR arms, respectively) 
and mRECIST (−38.1 [SD, 42.2] and −14.2 [SD, 36.7] in the 
ATEZO/BEV and SOR arms, respectively). A better DpR, 
as assessed by minimum percentage SLD changes, was ob-
served across baseline liver lesion size, including larger tu-
mors (≥7 cm; RECIST 1.1: −17.5 [SD, 29.3] and −4.5 [SD, 
22.0] in the ATEZO/BEV and SOR arms, respectively; mRE-
CIST: −27.9 [SD, 36.2] and −8.2 [SD, 28.0] in the ATEZO/
BEV and SOR arms, respectively).
3.2.2 | LD % change
DpR was also evaluated according to minimum percentage 
LD change in the largest liver lesion (Table  1; Table  S1). 
Patients in the ITT population and the subgroups per base-
line liver lesion sizes, including ≥7 cm, all exhibited similar 
trends, with a greater DpR across treatment arms and BICR 
response criteria. The mean (SD) minimum percentage LD 
change in the largest liver lesion was larger in the ATEZO/
BEV arm than in the SOR arm per both response criteria 
(RECIST 1.1: −27.0 [SD, 36.0] and −7.4 [SD, 29.1] in the 
ATEZO/BEV and SOR arms, respectively; mRECIST: −40.0 
[SD, 42.5] and −18.5 [SD, 38.4] in the ATEZO/BEV and 
SOR arms, respectively). In patients whose largest liver le-
sion was ≥7 cm, the mean minimum percentage LD changes 
in those lesions were also greater in the ATEZO/BEV arm 
than in the SOR arm per both RECIST 1.1 (−18.1 [SD, 29.6] 
and −5.8 [SD, 21.8] in the ATEZO/BEV and SOR arms, re-
spectively) and mRECIST (−29.0 [SD, 37.1] and −9.5 [SD, 
28.4] in the ATEZO/BEV and SOR arms, respectively).
3.3 | Complete responders
3.3.1 | Overall analysis
By RECIST 1.1, 25 patients (8%) in the ATEZO/BEV arm 
achieved a CR; 1 patient (0.6%) achieved a CR in the SOR 
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BEV and 4 patients (3%) receiving SOR achieved a CR.10 
The median TTCR to ATEZO/BEV was 7.0 months (range, 
1.2– 18.8  months) per RECIST 1.1 and 5.5  months (range, 
1.2– 16.8 months) per mRECIST (Table 2). For both response 
criteria, the median DoR was not reached in patients receiv-
ing ATEZO/BEV who had CRs. One patient with CR (per 
RECIST 1.1 and mRECIST) had disease progression and one 
with CR (per mRECIST) died due to pneumonia. For patients 
who had CRs per mRECIST while receiving SOR, the me-
dian TTCR was 4.8 months (range, 1.4– 9.2 months), and the 
median DoR had not been reached.
3.3.2 | Analysis by baseline characteristics
The characteristics of patients with a CR were generally sim-
ilar to those of the ITT population per both response criteria, 
except that a smaller proportion (≥10% difference) of these 
patients had a history of alcohol use; MVI, EHS, or both; or 
no prior local therapy (Table 3). CRs per RECIST 1.1 and 
mRECIST were observed with ATEZO/BEV across all eti-
ologies and baseline BCLC stage, regardless of the number 
of prior LRTs and tumor size. Patients receiving SOR who 
had a CR per mRECIST did not exhibit EHS or MVI at study 
entry.
3.3.3 | Analysis by largest target liver 
lesion size
The mean baseline SLD was lower in patients with CR re-
ceiving ATEZO/BEV than in the ITT population by both re-
sponse criteria (RECIST 1.1: 2.6 [SD, 1.4] cm vs. 8.3 [SD, 
6.0] cm, respectively; mRECIST, 5.0 [SD, 5.1] cm vs. 7.9 
[SD, 5.6] cm, respectively; Table 4). The mean (SD) largest 
liver lesion size was also smaller in patients with CR than 
those in the ITT population per RECIST 1.1 and mRECIST. 
When comparing RECIST 1.1 and mRECIST, the mean base-
line SLD in patients with CR receiving ATEZO/BEV was 
longer per mRECIST than per RECIST 1.1 (5.0 [SD, 5.1] cm 
vs. 2.6 [SD, 1.4] cm, respectively). Similarly, the mean larg-
est liver lesion size in patients with CR receiving ATEZO/
BEV was also larger per mRECIST than per RECIST 1.1 (4.8 
[SD, 4.2] cm vs. 2.3 [SD, 1.0] cm, respectively). In patients 
with larger lesions (≥5  cm), CRs per mRECIST were ob-
served only with ATEZO/BEV. Patients with CR per mRE-
CIST receiving SOR had smaller mean baseline SLD and 
largest liver lesion size than patients receiving ATEZO/BEV 
(4.0 [SD, 1.0] cm vs. 5.0 [SD, 5.1] cm and 2.8 [SD, 1.8] cm 
vs. 4.8 [SD, 4.2] cm, respectively).
A case report of the difference between CR per mRECIST 
and PR per RECIST 1.1 is illustrated in Figure 2. Additional 
examples of patients who achieved a CR per mRECIST and a 
PR per RECIST 1.1 are shown in Figure S1.
4 |  DISCUSSION
Improving survival is one of the most important objectives 
of cancer treatment. Potential variables that could be sur-
rogates are of interest and are currently under investigation. 
One proposed surrogate is ORR. This variable is one of the 
most commonly used parameters on which clinical decisions 
are based; knowing whether a tumor has responded to treat-
ment by showing a decrease in size or necrosis is important 
for patients and physicians to decide whether to continue or 
discontinue therapy.16 Although most of the literature on 
ORR as a surrogate of OS has mainly focused on LRTs, there 










Median time to CR (range), months 7.03 (1.2– 18.8) 9.2 (9.2– 9.2) 5.5 (1.2– 16.8) 4.8 (1.4– 9.2)
Duration of response, months
Patients without progression or death at 
cutoff, n (%)
18 (72) 1 (100) 27 (69) 2 (50)
Median (95% CI) NE (14.5- NE) NE (NE- NE) NE (21.4- NE) 17.9 (15.4– 17.9)
Range 2.6+ to 22.4+ 17.7+ to 17.7+ 2.6+ to 23.6+ 7.4+ to 17.9+
6- months analysis
Patients remaining at risk 22 1 35 4
Event- free rate (95% CI), % 96 (88– 100) 100 (100– 100) 97 (92– 100) 100 (100– 100)
Abbreviations: +, censored; ATEZO, atezolizumab; BEV, bevacizumab; BICR, blinded independent central review; CI, confidence interval; CR, complete response; 
mRECIST, HCC- modified Response Evaluation in Solid Tumors; NE, not evaluable; PR, partial response; RECIST 1.1, Response Evaluation Criteria in Solid Tumors 
version 1.1; SOR, sorafenib.
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Median age (range), year 64 (26– 88) 62 (37– 84) 70 (70– 70) 63 (37– 87) 71 (62– 78)
Age ≥65 year, n (%) 161 (48) 9 (36) 1 (100) 15 (39) 3 (75)
Men, n (%) 277 (82) 20 (80) 1 (100) 31 (80) 4 (100)
Race, n (%)
Asian 188 (56) 16 (64) 0 28 (72) 1 (25)
White 123 (37) 9 (36) 1 (100) 11 (28) 3 (75)
Region, n (%)
Asia (excluding Japana ) 133 (40) 13 (52) 0 24 (62) 0
Rest of world 203 (60) 12 (48) 1 (100) 15 (39) 4 (100)
Tobacco use history, n (%)
Never 130 (38) 9 (36) 0 15 (39) 0
Current 54 (16) 3 (12) 0 5 (13) 2 (50)
Previous 152 (45) 13 (52) 1 (100) 19 (49) 2 (50)
Alcohol use history, n (%)
Never 121 (36) 15 (60) 0 23 (59) 1 (25)
Current 48 (14) 1 (4) 0 2 (5) 1 (25)
Previous 166 (50) 9 (36) 1 (100) 14 (36) 2 (50)
ECOG PS at screening, n (%)
0 209 (62) 19 (76) 1 (100) 28 (72) 3 (75)
1 127 (36) 6 (24) 0 11 (28) 1 (25)
Child- Pugh score, n (%)
A5 239 (72) 19 (76) 1 (100) 32 (82) 4 (100)
A6 94 (28) 6 (24) 0 7 (18) 0
APF ≥400 ng/ml, n (%) 126 (38) 6 (24) 1 (100) 12 (31) 3 (75)
Prior local therapy for HCC, 
n (%)
161 (48) 17 (68) 0 24 (62) 1 (25)
Prior TACE/DEB- TACE, n (%)
0 205 (61) 10 (40) 1 (100) 18 (46) 3 (75)
1 or 2 66 (20) 10 (40) 0 13 (33) 1 (25)
≥3 65 (19) 5 (20) 0 8 (21) 0
BCLC stage at study entry, n (%)
Stage A1 8 (2) 2 (8) 0 2 (5) 0
Stage B 51(15) 5 (20) 0 8 (21) 1 (25)
Stage C 277 (82) 18 (72) 1 (100) 29 (74) 3 (75)
Etiology of HCC, n (%)
HBV 164 (49) 15 (60) 0 24 (62) 1 (25)
HCV 72 (21) 6 (24) 0 9 (23) 0
Nonviral 100 (30) 4 (16) 1 (100) 6 (15) 3 (75)
MVI, n (%)b 129 (38) 7 (28) 1 (100) 15 (39) 1 (25)
EHS, n (%)b 212 (63) 14 (56) 1 (100) 22 (56) 1 (25)
MVI, EHS, or both, n (%) 258 (77) 16 (64) 1 (100) 27 (69) 1 (25)
Abbreviations: APF, alpha- fetoprotein; ATEZO, atezolizumab; BCLC, Barcelona Clinic Liver Cancer; BEV, bevacizumab; BICR, blinded independent central review; 
CR, complete response; DEB- TACE, doxorubicin- eluting beads transarterial chemoembolization; ECOG PS, Eastern Cooperative Oncology Group performance 
status; EHS, extrahepatic spread; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ITT, intent- to- treat; mRECIST, HCC- modified 
Response Evaluation Criteria in Solid Tumors; MVI, microvascular invasion; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SOR, sorafenib; 
TACE, transarterial chemoembolization.
aJapan is included in the rest of the world.
bAt study entry, per electronic case report form.






































































































































































































































































































































































































































































































































































































































































































































































5444 |   SALEM Et AL.
is growing interest in ORR in the literature about systemic 
therapies.17,18 IMbrave150 showed statistically significant 
and clinically meaningful improvement in OS and PFS with 
ATEZO/BEV versus SOR, and several observations in ORR 
and DpR, as well as in which patients achieved CR, can be 
gleaned from this post hoc analysis.
IMbrave150 used both RECIST 1.1 and mRECIST meth-
odologies to assess PFS (RECIST 1.1, primary endpoint) and 
response. A statistically significantly greater increase in ORR 
was observed with ATEZO/BEV versus SOR as assessed by 
BICR per RECIST 1.1 and mRECIST.10 The disease control 
rates were 73.6% and 55.3% with ATEZO/BEV and SOR, re-
spectively. At the time of data cutoff for the primary analysis, 
responses were ongoing in 87% and 68% of responders in the 
ATEZO/BEV and SOR arms, respectively.10 Similar trends 
were observed using mRECIST. Per both response criteria, 
the median DoR had not yet been reached in the ATEZO/
BEV arm versus 6.3 months in the SOR arm. The probability 
of having DoR ≥6 months was >80% in the ATEZO/BEV 
arm per both response criteria. This observation aligns with 
other studies, in which sustained and clinically relevant re-
sponses have been observed.19
The increase in ORR was maintained in the updated 
data. The ATEZO/BEV ORRs of 35% and 30% by mRE-
CIST and RECIST are clinically meaningful and confirm 
the cytotoxic effect of the combination. Correlation between 
mRECIST and RECIST 1.1 was maintained for lesions up to 
5  cm. However, expectedly, mRECIST responses appeared 
greater than RECIST once lesions exceeded 5 cm. This result 
is likely explained by avascular hepatic scarring, which can 
be observed in cirrhotic livers following treatment, simulta-
neously permitting mRECIST CR but preventing RECIST 
1.1 CR (see Figure 2). Of interest, patients having received 
one or two LRTs appeared to have higher ORR than those 
receiving no or ≥3 LRTs. This result could be explained by 
a self- selection bias, where patients never having received 
an embolization have unknown biological behavior, whereas 
those with ≥3 LRTs may have been treated excessively, with-
out a natural transition from LRTs to systemic therapy. Hence, 
those who have received one or two treatments represent a 
self- selected group and the ideal patient population, in whom 
biologic behavior is observed, liver functions are maintained, 
a natural transition to systemic therapy is made, and long- 
term outcomes are optimized by allowing for sequential first- 
and second- line drug therapies. A non- systematic review 
has shown that some patients may benefit from early switch 
(i.e., after one or two TACE treatments) to systemic therapies 
rather than repeating treatment with LRT.20
As opposed to simply reporting the SLD when perform-
ing response assessments, analyzing the largest index lesion 
(i.e., target liver lesion) is of clinical importance.21 Large 
(≥7 cm) index lesions represent a significant clinical chal-
lenge and are assumed to be reflective of more aggressive 
tumor biology, lower response rates, and a tendency for 
F I G U R E  2  Example of a patient 
with HCC with multifocal bilobar disease 
that was highly vascularized. At baseline, 
the patient had multifocal bilobar disease 
that was highly vascularized, with a tumor 
that measured 14.1 cm. On the follow- up 
scan 9 months later, the tumor had shrunk 
to 5.0 cm. The patient achieved a CR per 
mRECIST and a PR per RECIST 1.1. No 
prior locoregional therapy was reported, 
and treatment was still ongoing as of the 
date cutoff (August 2019) with a treatment 
duration of 294 days. CR, complete 
response; HCC, hepatocellular carcinoma; 
mRECIST, HCC- modified Response 
Evaluation Criteria in Solid Tumors; PR, 
partial response; RECIST 1.1, Response 
Evaluation Criteria in Solid Tumors version 
1.1
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LRT as first- line options in liver- only disease. Interestingly, 
the ATEZO/BEV combination generated a respectable 21% 
and 26% ORR by RECIST 1.1 and mRECIST, respectively, 
in patients with these challenging tumors, suggesting a role 
for systemic therapy in patients with larger lesions that 
are not candidates for, or have progressed with, LRTs. It 
further introduces the potential role of systemic agents in 
the downstaging setting, which is also space traditionally 
reserved for LRTs.22- 24 With smaller tumors, the thresh-
old for tumor reduction to meet response criteria is lower, 
which may explain the high response rate and longer PFS 
observed with SOR in lesions traditionally characterized as 
small (i.e., <3 cm).
In total, per RECIST 1.1, we observed a greater DpR with 
mean minimum percentage SLD changes of −27.3 (SD, 38.8) 
and −6.1 (SD, 29.4) in the ATEZO/BEV and SOR arms, re-
spectively. The mean minimum percentage SLD change was 
−38.1 (SD, 42.2) and −14.2 (SD, 36.7) in the ATEZO/BEV 
and SOR arms, respectively, per mRECIST. These findings 
are clinically applicable, as they further reinforce the concept 
that although achieving a PR should be one goal of treatment, 
even minor reductions (not reaching PR threshold) in tumor 
size could translate to downstaging to ablation or transplant 
criteria. As an example, a patient with T3 disease and three 
lesions (2.5, 2.5, and 3.2  cm) could be downstaged to T2 
transplant criteria with a 10% reduction of the 3.2 cm lesion, 
well within the observed DpR with ATEZO/BEV.23 This 
DpR was also maintained in larger index lesions (≥7  cm), 
with a mean minimum percent SLD change of −17.5% by 
RECIST 1.1 and −27.9% by mRECIST. The well- described 
high ORR of cytotoxic LRTs for lesions ≥7 cm and the mean-
ingful DpR and DoR with ATEZO/BEV suggest that these 
combinations represent the next natural evolution of clinical 
investigation.16
In a disease with historically low CR rates, it was nota-
ble that 25 (8%) and 39 (12%) patients achieved a CR per 
RECIST 1.1 and mRECIST, respectively, with ATEZO/BEV 
versus 0.6% and 3%, respectively, with SOR. The 6- month 
event- free rate was >90%, and the median DoR had not yet 
been reached. Furthermore, patients achieved CR across all 
etiologies and BCLC stage at entry, regardless of the number 
of prior LRTs and tumor size. Interestingly, complete tumor 
resolution was also seen in patients with MVI, an observation 
usually made only with LRTs such as Y90.25,26 In patients 
demonstrating a prolonged CR, this observation is clinically 
meaningful and may confer a systemic therapy holiday (with 
strict imaging follow- up). This concept is particularly rele-
vant for patients who have limited options, in whom the pres-
ervation of future downstream treatment should be a strong 
consideration. In contrast, there were no mRECIST CRs in 
the SOR control arm in patients with baseline MVI or EHS, 
but the small number of patients achieving CR with SOR lim-
its the interpretation of these data.
Recent guidance from an American Association for the 
Study of Liver Diseases panel of experts on clinical trial de-
sign recommended that the primary endpoint for systemic 
therapies should be OS, with PFS as a coprimary endpoint.27 
For the assessment of ORR in response to systemic thera-
pies, both RECIST 1.1 and mRECIST should be used.27 
These recommendations are consistent with the design of the 
IMbrave150 study and the report herein.10
There are strengths and limitations to this analysis. 
Strengths include the source dataset being a large, multicenter, 
international phase 3 trial, with BICR using both RECIST 1.1 
and mRECIST criteria. This is also the first analysis in HCC 
to describe the DpR and the potential clinical implications 
(e.g., downstaging), a concept usually reserved for colorectal 
cancer analyses. To further support the clinical relevance of 
these analyses, the data were stratified with granularity that 
permitted an exploratory look of patients with HCC managed 
in the real- world setting. Limitations include the post hoc, 
retrospective analyses, with limited sample sizes in some 
subgroups. The presence of scarring identified at imaging 
following treatment may have resulted in the underreport-
ing of CR and PR by RECIST 1.1, discrepancies with mRE-
CIST, or both. There is a need for prospective investigations 
in bridging and downstaging groups, as well as combination 
LRT or systemic therapies. Furthermore, little is known 
about transplantation following immunotherapies; this field 
requires further study.
5 |  CONCLUSION
The data reported here describe the deeper ORR benefit that 
can be achieved with ATEZO/BEV than with SOR. Overall, 
responses achieved with ATEZO/BEV may be more clini-
cally meaningful to patients with unresectable HCC and to 
clinicians who treat their patients with this combination as 
part of their standard of care. The findings also potentially 
introduce the concept of downstaging in patients who are in-
eligible for, or have had treatment failure with, LRTs. Further 
investigations in the neoadjuvant setting to resection, abla-
tion, and transplant are warranted.
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